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The aim of our study was to evaluate the eﬃcacy and tolerability of a ciproﬂoxacin-based regimen for H. pylori eradication
failures as an alternative to bismuth based quadruple therapy. Methods. Design: prospective single-center study. Patients in
whom a ﬁrst eradication trial with omeprazole/esomeprazole, clarithromycin plus amoxicillin or tinidazole/metronidazole had
failed were included. H. pylori status: established by histology, rapide urease test and polymerase chain reaction. Intervention:
esomeprazole 20mg, ciproﬂoxacin 500mg, and metronidazole 500mg, administered together before breakfast and dinner for 10
days. Susceptibility testing was performed by the Epsilometer test. Ciproﬂoxacin resistance was deﬁned as a MIC of ≥1µg/mL.
Eradication was established by a negative 13C-UBT and 4–6 weeks post-therapy. Eﬃcacy and side eﬀects were determined. Results.
34 patients were enrolled, 32 completed the study. Compliance was excellent (100%). Side eﬀects were mild. Ciproﬂoxacin-based
therapy cured 65% (22/34) of patients by intention to treat and 69% (22/32) per protocol analysis. The prevalence of ciproﬂoxacin
resistance was 8%. Conclusions. The eﬀectiveness of ciproﬂoxacin-based therapy was greatly reduced despite the high prevalence
of ciproﬂoxacin sensitive H. pylori strains. Bismuth based quadruple therapy still remain the best choice as a “rescue” regimen in
our region.
1.Introduction
Helicobacter pylori infection is the main cause of gastroduo-
denal diseases. Infected individuals develop chronic active
gastritis that in a subset of patients might progress to
sever complications. The cure of H. pylori infection changes
the natural history of the gastritis. Antibiotic combination
therapy for H. pylori eradication is now the standard of
care for patients positive for the infection. Guidelines for
treatment regimens have been proposed by the European
Helicobacter pylori Study Group [1].
Protonpumpinhibitors(PPIs-)clarithromycin-amoxicil-
lin or metronidazole treatment is the recommended ﬁrst
choice treatment in populations with less than 15 to 20%
clarithromycin resistance. In populations with less than
40% metronidazole resistance, PPI-clarithromycin-metron-
idazole is preferable. Quadruple treatments are alternative
ﬁrst choice treatments. Bismuth-containing quadruple treat-
ments remain the best second choice regimen, if available.
Previous studies demonstrated that in northern Sardinia,
1-weektripletherapiesconsistingofaPPIandmetronidazole
and clarithromycin or amoxicillin have produced lower
than acceptable cure rates, ranging from 55% to 57% [2].
Responsible for most of the reduction in cure rates was
the antibiotic resistance to metronidazole, amoxicillin, or
clarithromycin. However, resistance to metronidazole can
frequently be overcome by increasing the dose and duration
of treatment, whereas clarithromycin resistance cannot [3].2 Gastroenterology Research and Practice
Colloidal bismuth subcitrate-based twice-a-day quadruple
therapy demonstrated to be an excellent primary therapy
with an intention-to-treat (ITT) cure rate of 95% (95%;
CI: 90–98%) and 98% per protocol (PP), irrespective of
diagnosis, age, prior treatment failure, or smoking status [4].
In addition the colloidal bismuth subcitrate-based twice-a-
day quadruple regimen showed a high eﬃcacy for patients
failing one or more courses of H. pylori treatment in Sardinia
[5].
Other combinations using diﬀerent medications have
been proposed as “rescue” therapies including therapy with
ﬂuoroquinolones [6–9]w i t haP P I[ 10], reserved in general,
for patients who fail two courses of treatment. However, in
few studies the eﬃcacy of ciproﬂoxacin-based regimen was
explored [11–15].
In order to oﬀer an alternative to our patients with H.
pylori infection after a treatment failure we evaluated the
eﬃcacy and tolerability of a Ciproﬂoxacin-based regimen.
2. Methods
2.1. Patients. This study was a prospective, single center trial
for treatment of consecutive patients in whom a ﬁrst erad-
ication trial with omeprazole/esomeprazole, clarithromycin,
and amoxicillin (14 patients) or omeprazole/esomeprazole,
clarithromycin, and tinidazole/metronidazole (20 patients),
had failed to eradicate H. pylori infection.
2.2. Exclusion Criteria. Patients who received bismuth com-
pounds, antisecretory drugs, or antibiotics during the 4
weeks before endoscopy were excluded. Other exclusion
criteria included pregnancy or lactation; regular use of
nonsteroidal anti-inﬂammatory drugs including acetylsali-
cylic acid and/or corticosteroids, malignancy, severe liver,
heart, kidney or endocrine diseases, and any other clinically
signiﬁcant medical condition, alcohol abuse, drug addiction,
historyofallergytoanyofthedrugusedinthestudy.Written
informedconsentwasobtainedfromallparticipants,andthe
study was conducted according to the guidelines of the local
ethics committee.
2.3. Deﬁnition of H. pylori Infection. Pretreatment H. pylori
infection was deﬁned as a positive rapid urease test (CP-
test, Yamanouchi S.p.A., Milan, Italy), the presence of H.
pylori on histological examination, and by polymerase chain
reaction (PCR) analysis. Posttreatment success was deﬁned
by a negative 13C-UBT 4-5 weeks after completing therapy.
2.4. Histology. Two biopsy specimens were taken from the
antrum, one from the angulus and one from the gastric
corpus for histology. Biopsy specimens were immediately
ﬁxed in 10% buﬀered formalin and subsequently stained
with hematoxylin and eosin and with Giemsa to assess the
presence of H. pylori.
2.5. 13C-Urea Breath Test. The 13C-UBT was performed
according to a standardized protocol, the sensitivity, and
speciﬁcity of which have been reported to be of 95% [16].
Allbreathtestswereanalyzedatthesamelaboratorybyusing
a single gas isotope ratio mass spectrometer (ABCA, Europe
Scientiﬁc, Crewe, UK).
2.6. Microbiology. One antral biopsy was immediately trans-
ported at room temperature in a Portagerm pylori (bioMer-
ieux, S.p.A., Rome, Italy) for culture. Biopsies were streaked
on Columbia agar plates (bioMerieux) and were incubated
for 3–5 days at 37◦C, 12% CO2 (Campy Pak Plus, BBL
BectonDickinson,Cockesville,MD)and100%relativehum-
idity. The identity of H. pylori was conﬁrmed by colony
appearance, Gram stain, and positive biochemical tests
(oxidase, catalase, and urease). The minimum inhibitory
concentration (MIC) was determined by the E-test (AB
Biodisk, Uppsala, Sweden) following the manufacturer’s in-
structions in Columbia agar plates (90mm) containing 5%
sheep blood as previously described [2]. E-test strips were
asepticallyplacedontodriedsurfacesoftheinoculatedplates.
Test results were read after incubation at 37◦Cf o r7 2 h
in a standard atmosphere. MICs were determined by the
intercept of the elliptical zone of inhibition with the graded
E-teststrip.ThebreakpointsusedtodeﬁneresistantH.pylori
were for amoxicillin ≥8µg/mL, clarithromycin ≥2µg/mL,
metronidazole ≥2µg/mL, and for tetracycline ≥2µg/mL,
respectively [2].
Thecutoﬀconcentrationsusedtodeﬁneciproﬂoxacinre-
sistance was ≥1µg/mL [17, 18]. Post-treatment culture of
biopsy specimens and antibiotic susceptibility tests were not
done.
2.7. Genomic Characterization of H. pylori by Polymerase
Chain Reaction. Genomic DNA was extracted from gastric
biopsies collected one from the antrum and one from
the corpus using the QIAamp Tissue kit (QIAGEN, Inc.,
Chatsworth, CA, USA), according to the manufacturer’s
instructions.
A set of primers speciﬁc for the H. pylori vacA gene
(VAG-F: 5 -CAA TCT GTC CAA TCA AGC GAG-3  and
VAG-R: 5 -GCG TCA AAA TAA TTC CAA GG-3 )w i t ha
reported sensitivity of 98.4% [19] was used to amplify a 570-
bp product for m1 and 645-bp product for m2 from the
middle region of the vacA gene [20].
2.8. Medication. The intervention consisted of esomeprazole
20mg, plus ciproﬂoxacin 500mg, and metronidazole 500mg
bid. The choice of ciproﬂoxacin was based on the fact that
the eﬃcacy of ciproﬂoxacin-based regimen was evaluated in
a small number of studies [11–15] and never in Sardinia.
No treatment was administered thereafter. All drugs were
administered together before breakfast and dinner for 10
days. The duration of 10 days was arbitrarily decided.
2.9. Patient Compliance. The patients were evaluated for
compliance at followup, after completing treatment, by a
physician, both by direct questioning and by pill count and
were scored according to the number of days the patient
took the study medication. All patients were interviewed
for possible side eﬀects by questionnaire. Side eﬀects wereGastroenterology Research and Practice 3
Table 1: Intervention status of patients enrolled in the study.
Status Patients∗
Received intervention 34
Lost to followup 2
Completed trial 32
Intervention ineﬀective 10
Cure Rate ITT 65% (22/34)
95% CI 46–80
Cure Rate PP 69% (22/32)
95% CI 50–83
∗Patients in whom a ﬁrst eradication trial with omeprazole/esomeprazole,
clarithromycin, and amoxicillin (14 patients) or omeprazole/esomeprazole,
clarithromycin, and tinidazole/metronidazole (20 patients) had failed to
eradicate H. pylori infection.
ITT: intention-to-treat analysis; PP: per protocol analysis; CI: Conﬁdence
Interval.
Table 2: Prevalence of antibiotic resistance of H. pylori isolates
after treatment with omeprazole/esomeprazole, clarithromycin,
and amoxicillin or omeprazole/esomeprazole, clarithromycin, and
tinidazole/metronidazole.
Antibiotics MIC cut oﬀ (number of H. pylori-resistant strains)
Amoxicillin >8µg/mL (2 > 8µg/mL)
Clarithromycin ≥2µg/mL (1 > 256µg/mL)
Metronidazole >8µg/mL (3 > 256µg/mL)
Ciproﬂoxacin ≥1µg/mL (2 > 32µg/mL)
Tetracycline ≥2µg/mL (0)
MIC: minimum inhibitory concentration.
gradedasmild(didnotlimitdailyactivities),moderate(lim-
ited daily activities to some extent), or severe (made daily
activities all but impossible).
2.10. Statistical Analysis. For quantitative variables, per-
centage and 95% conﬁdence interval (CI) were calculated.
Analysis of H. pylori eradication eﬃcacy was performed
on an “intention-to-treat” (ITT) basis including all eligible
patients enrolled in the study and on a “per-protocol” (PP)
basis excluding patients lost to the followup.
3. Results
A total of 34 consecutive patients fulﬁlling the inclusion
criteriawereenrolledinthestudy(12males,medianage55,6
years range 25–75 years).
No one patient had peptic ulcer disease, gastric, nor
duodenal erosions. All patients had experienced dyspeptic
symptoms. Thirty-two patients took medications as pre-
scribed and H. pylori eradication status was assessed after
therapy. Two patients were lost to followup.
3.1.H.pyloriEradication. Ciproﬂoxacin-basedtherapycured
65% (22/34; 95% CI: 46–80) of patients with H. pylori
infection by ITT analysis and 69% (22/32; 95% CI: 50–83)
by PP analysis (Table 1). Patients harboring ciproﬂoxacin-
resistant H. pylori strains were not cured. Treatment failures
by ciproﬂoxacin-based “rescue” therapy were cured with
bismuth-based quadruple therapy bid.
3.2. Patient Compliance and Side Eﬀects. Overall tolerability
was good. Excellent compliance (100%) was achieved in all
cases. No one pill was returned by the patients. Data on
side eﬀects were available for all 32 treated patients. No one
patient complained severe side eﬀects. Fourteen patients (9
women)developedmildsideeﬀectssuchasfatigue,diarrhea,
nausea, vomiting, or stomachache, making working more
diﬃcult in the ﬁnal treatment days.
3.3. Antibiotic H. pylori Resistance. Pretreatment culture
was available for 26 patients. Susceptibility testing was not
possible in 6 cases because of absence of microbial growth
due to insuﬃcient gastric tissue. Two patients (8%) harbored
H. pylori resistant to ciproﬂoxacin, and amoxicillin, one
H. pylori isolate (4%) was resistant to clarithromycin and
3 (12%) to metronidazole. All strains were susceptible to
tetracycline (Table 2).
3.4. Genomic Characterization of H. pylori Organisms . DNA
analysis by PCR ampliﬁed the middle region of vacA gene in
all gastric samples. In 29 cases the genomic fragment of vacA
m2 subtype, more prevalent in our region [20, 21], was amp-
liﬁed and in 6 cases vacA m1 subtype.
4. Discussion
Despite the large number of studies, identiﬁng an optimal
therapeutic regimen for H. pylori infection remains a
challenge. Quadruple therapy consisting of a PPI combined
with bismuth (525mg four times daily) and two antibiotics
(e.g., metronidazole 250mg four times daily and tetracycline
500mg four times daily) given for 10 to 14 days has been
generally used as the optimal second-line therapy after pro-
ton pump inhibitor clarithromycin amoxicillin failure and
has been the recommended rescue regimen in several guide-
lines. The introduction of combination capsules containing
bismuth-quadrupletherapyhasledtoaresurgenceininterest
in bismuth-containing regimens as appropriate ﬁrst-line
therapy [22–24].
Quadruple therapy is especially appropriate as initial
therapy in areas in which the prevalence of resistance to
clarithromycin or metronidazole is greater than 20% or in
patients with recent or repeated exposure to clarithromycin
or metronidazole for any reason [25]. We previously showed
that a modiﬁed schedule in which quadruple therapy
was given twice-a-day for 14 days (i.e., with the noon
and evening meals) yielded high cure rates [4], despite
the fact that our geographic area has a high background
prevalence of antibiotic resistance [2]. For example the
reported prevalence of antibiotic resistance in Sardinia was
29% for metronidazole, 26% for amoxicillin, 23% for clar-
ithromycin, 14% for tetracycline, and 33% for doxycycline4 Gastroenterology Research and Practice
[2]. In addition midday bismuth-subcitrate-based twice-a-
day quadruple therapy demonstrated to be excellent also as a
“rescue” therapy. The reported cure rates were for intention
to treat = 93% (95% CI = 84% to 98%) and per protocol =
97% (95% CI = 89% to 100%) [5].
In order to oﬀer an alternative to quadruple regimen to
our patients we evaluated the eﬃcacy and tolerability of a
ciproﬂoxacin-based regimen in patients with H. pylori infec-
tion after a treatment failure.
Ciproﬂoxacin belongs to the ﬂuoroquinolone group of
antibiotics that are generally used as part of rescue therapy
for treating H. pylori infections when ﬁrst- and second-line
therapies have failed [26, 27]. Resistance to ﬂuoroquinolones
is generally very low (<10%) worldwide [28]. In addition
ciproﬂoxacin has low MICs against H. pylori and is highly
active in vitro in eradicating the organism [29], and high
levels of ciproﬂoxacin have been found in gastric tissue
biopsy specimens [30].
In small early trials ciproﬂoxacin failed to show eﬃcacy
againstH.pyloribecauseofareducedantibioticactivityinan
acid pH environment due to increasing ionization [31, 32].
Based on this information, in further trials, in order to
enhance in vivo activity, ciproﬂoxacin was administered with
acid-suppressing drug such as omeprazole and cure rates of
70%wereobtained[9].Similarresults(70%)wereconﬁrmed
in Europe given ciproﬂoxacin as a component of a sequential
therapy for patients with metronidazole-resistant strains
[12]. In Iran a regimen consisting of omeprazole 20mg plus
bismuth subcitrate 120mg 2 tab. plus ciproﬂoxacin 500mg
b i da c h i e v e da ne r a d i c a t i o nr a t eo f6 7 . 1 %[ 14]. In the same
country similar results (65,4% and 70% by ITT and PP
analyses) were obtained given omeprazole and amoxicillin,
both twice daily for two weeks and ciproﬂoxacin twice a day
for the ﬁrst week [15].
In our study, ciproﬂoxacin-based therapy cured 65%
(22/34) of patients with H. pylori infection by ITT analysis
and 69% (22/32) per PP analysis beside the low rate of
ciproﬂoxacin resistance among strains (2 out 26).
There are no data about resistance of H. pylori to
ciproﬂoxacin in our country; however, primary resistance
to levoﬂoxacin in Italy has been demonstrated to be low
[33]. The likelihood of treatment eradication success can
be improved through the use of antibiotics that are known
to be most eﬀective in the region. According to this notion
reported eradication rates with levoﬂoxacin-250 sequential
therapy and with levoﬂoxacin-500 sequential therapy were
97% and 96% by the ITT analyses in Italy [34].
In the other hand G¨ uzelbulut et al. have shown that in
Turkey, a modiﬁed sequential therapy regimen, consisting
of PPI plus amoxicillin (5 days) followed by PPI plus
levoﬂoxacin (5 days) was not superior (ITT: 67%) over
standard sequential therapy for H. pylori eradication [35].
We do not have a convincing explanation about the
numerous factors that could have aﬀected eradication rates
in our study. We may suppose that the drug formulation
used, chemical properties of the drug, its stability at varying
pH, concentrations of active drug in the gastric tissue,
frequency, and timing of drug or the regimen combination
c o u l dh a v ei n t e r f e r e di nt h eﬁ n a le ﬃcacy of ciproﬂoxacin-
based treatment.
In conclusion, based on the results of our study we have
to consider ciproﬂoxacin-based treatment a nonacceptable
option as a “rescue” treatment in our region.
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